This is an original report of a Children's Oncology Group phase I study of valproic acid, a histone deacetylase inhibitor, in children with recurrent/refractory solid tumors, including CNS tumors. We showed that chronic maintenance of valproic acid trough concentrations of 100-150 mcg/ml was associated with dose-limiting toxicities, but targeting valproic acid trough concentrations of 75-100 mcg/ml was well tolerated. Two confirmed objective tumor responses (1 PR, 1 MR) and one unconfirmed MR in children with brain tumors were observed; two of these three patients had increased histone acetylation in their peripheral blood monocytes. We conclude that valproic acid deserves further studies as a novel agent in pediatric cancers, especially in combination with radiation treatment, chemotherapeutic drugs, or biologic agents in children with CNS tumors.
INTRODUCTION
Chromatin remodeling is critical for epigenetic regulation of gene expression.
Acetylation of histones' amino-terminal tails by histone acetyltransferase relaxes the chromatin for transcription (1) , and removal of acetyl groups by histone deacetylase (HDAC) compacts the chromatin and represses transcription (2) . Histone hypoacetylation and inappropriate transcriptional repression are hypothesized to be key contributors to the development of human cancers (3, 4) , and global hypo-acetylation of histone H4 has been identified as an abnormal epigenetic signature common to many malignancies (5) . HDAC inhibitors (HDACi), which are hypothesized to reactivate expression of critical genes aberrantly silenced during tumorigenesis, have been shown to cause pleiotropic effects on human cancer cells, including apoptosis, cell cycle arrests, and differentiation (3, 4, 6) .
Valproic acid (VPA), an anti-convulsant widely used in children for over 30 years (7), was recently discovered to be an HDACi (8, 9 ) that inhibits growth of human cancers (9) (10) (11) (12) , including pediatric solid tumors (13) (14) (15) . Functional studies (8, 9, 11, (16) (17) (18) have confirmed that HDAC inhibition and histone hyper-acetylation are essential for VPA's anti-tumor activity. Several phase 1 and 2 studies of VPA in adults with hematologic (19) (20) (21) (22) and solid malignancies (23) (24) (25) (26) (27) (28) (29) showed that VPA treatment, either as a monotherapy or combined with other agents, was reasonably well tolerated and resulted in some encouraging tumor responses. Most recently, a clinical trial combining VPA, radiation and chemotherapy for children with high-grade gliomas was reported (30) . In this trial, children with high-grade gliomas received radiation and six cycles of 
Pharmacokinetic Studies
Optional pharmacokinetic (PK) studies were performed in consenting patients on day 1, cycle 1 and again during cycle 1 after the targeted VPA concentration had been maintained for 2 consecutive weeks (steady state). Samples were obtained at 0.5, 1, 2, 4, 6, 8, 12, and 24 hours after the initial dose, and at -0.5, 0.5 1, 2, 4, 6, and 8 hours after the steady state dose. The fluorescent polarization immunoassay technique (31) using the AxSYM or TDx immuno-analyzer from Abbot Laboratory was used to determine VPA concentrations. The known inter-day coefficient of variation was < 5%
for the referenced assay. Samples were filtered through a Millipore Centrifree Ultrafiltration Device by spinning at 1,000-2,000 x g using a fixed angle centrifuge for determination of free VPA concentrations.
Non-compartmental methods were used to calculate the area under the concentrationtime curve (AUC), apparent total body clearance (CL/F), and apparent steady-state volume of distribution (V d /F) (F denoting the fraction of bioavailability).
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Research. with 162 mcg/ml of VPA for 24 hours were included as positive controls (32) .
RESULTS
Twenty six patients were enrolled, of whom 26 were eligible and 16 were fully evaluable for toxicity. Reasons that patients were inevaluable for toxicity included: unable to reach targeted VPA concentration (n=2), rapidly progressive disease (n=2), consented but never started therapy (n=1), withdrawal (n=3), toxicities unlikely to be related to VPA (n=1), and VPA concentration exceeding the targeted range (n=1). The first two patients in Cohort 1 failed to reach the targeted VPA concentration range after six dose escalations and were removed from study per initial design. As a result, the study was amended to allow continued dose escalation in the absence of DLT. However, because several patients in Cohort 1 required more than 5 (mean 3.8 ± 2.6) dose escalations to achieve VPA concentrations of 100-150 mcg/ml, VPA administration was increased from b.i.d. to t.i.d. in an attempt to attain the targeted VPA more promptly.
Research. grade-5 hemorrhage/hemothorax). The patient with the hemothorax had metastatic synovial sarcoma to the lung and was believed to have had an intra-tumoral hemorrhage. Six subsequent patients were enrolled into Cohort 0 (VPA troughs 75-100 mcg/ml) as per study design and did not experience any DLT. Enrollment into Cohort 2 (VPA troughs 150-200 mcg/ml) was not pursued because VPA trough concentrations of 100-150 mcg/ml were not well tolerated. 
Tumor Response
One confirmed partial response (PR) was observed in a patient with a biopsy confirmed thalamic GBM who was treated on Cohort 0 (VPA troughs 75-100 mcg/ml) for 7 months.
One confirmed minor response (46% reduction in bi-dimensional measurements) was observed in another patient with a brainstem glioma who was treated on Cohort 1 (VPA troughs 100-150 mcg/ml) for 5 months. Both responses were confirmed by central review. A third patient with a suprasellar desmoplastic infantile ganglioglioma showed a 39% reduction in bi-dimensional measurements (with a VPA concentration of 123 mcg/ml) at 9 weeks after study entry, but confirmation of a sustained response did not occur as the child was removed from study because of severe unexpected toxicities.
These toxicities were not attributed to VPA but instead to bacteremia and presumed acute adrenal insufficiency.
Pharmacokinetic Studies
Of the 25 patients who received protocol therapy, 14 received VPA syrup only, 1 received capsules only, and 10 received both syrup and capsules. Pharmacokinetic studies were obtained in four patients after the first dose of VPA, and the observed median half-life, clearance, and volume of distribution of total VPA were 11.0 +/-2.7
Research.
on These parameters were consistent with values previously reported in children receiving VPA for seizures (33) (34) (35) . Steady state PK was also studied in four patients. Steady state total VPA clearance was 8.0+/-2.4 ml/kg/hour, similar to first dose total VPA clearance. Steady state half-life (median 11.4 +/-3.3 hours) of total VPA was essentially identical to that observed with first dose. First dose peak free VPA levels varied between 4-6 mcg/ml and occurred 2-4 hours after dosing. First dose PK analysis could not be performed for free VPA because measured concentrations were very low (near the detection limit of 0.7 mcg/ml). Steady state free VPA clearance, 52.2 ± 43.9 ml/kg/hr (median ± SD), was greater than total VPA clearance. The steady state half-life (median 6.5 +/-1.3 hours) of free VPA was also shorter than that observed with total drug and was similar to what has been previously reported (36, 37) . All PK results are summarized in Table 4 .
There was no apparent direct correlation between VPA dose and steady state total VPA concentration ( Figure 1A Similarly, for patients maintaining VPA concentration between 75-100 mcg/ml, the mean steady state VPA doses in patients taking syrup only (n = 4) versus syrup and capsules (n= 2) were 17.5 +/-2.9 mg/kg and 12.5 +/-3.5 mg/kg (p = 0.13), respectively. There were an insufficient number of patients to determine whether VPA formulations had a statistically significant impact on the observed PK parameters or the number of dose escalations required to reach targeted VPA concentrations.
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The following samples were available for assessment of histone acetylation: 7 matching 
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Copyright © 2010 American Association for Cancer Research measurements were 3.4 ± 2.6%, and 14.9 ± 10.5%, respectively. Given the minimal variability in the pre-treatment histone acetylation measurements, we therefore used the mean pre-treatment AcH3 and AcH4 values to estimate the changes in AcH3 and AcH4
for the 3 post-treatment samples without matching pre-treatment samples. Five patients had reduced post-treatment AcH3 and AcH4 levels in their PBMCs. Five patients showed increased AcH3 and AcH4 levels, which ranged from 18% to 1100% (AcH3).
The patient who received VPA for 7 months and achieved a PR had the most dramatic increase in AcH3 and AcH4 (Table 5) .
DISCUSSION
VPA has pre-clinical activity against many human cancers, and several phase 1 and 2 trials of VPA-containing regimens in adults with hematologic malignancies have response rates of 10-22% (19, 21) . In adults with solid tumors, stable disease has been observed after VPA monotherapy (24, 26, 28) , and response rates of 22 to 64% have been seen when VPA was combined with chemotherapy (25, 29) . VPA-associated antitumor activity has been reported in a child with a glioblastoma multiforme (GBM) who had a CR for 12 months (38) and in 3 additional children with GBMs who received VPA monotherapy for progressive GBM after radiation and chemotherapy (30).
Our study design was based on pre-clinical studies that suggested the threshold VPA concentration associated with anti-tumor activity exceeded 100 mcg/ml (10, 14, 32, 39, 40) and on the reports of children with GBM who responded to VPA monotherapy who had VPA concentrations between 100-160 mcg/ml (30, 38) . The first challenge
Research. Figure 1A This figure demonstrates a lack of correlation between valproic acid dose and steady state total valproic acid concentration. Patients receiving valproic acid twice daily required more dose escalations and higher final doses to achieve targeted concentrations than those receiving the drug three times daily. C ss = steady state concentration; VPA = valproic acid; SD = standard deviation; TID = three times daily; BID = twice daily.
Figure Legends

Figure 1B
This figure illustrates the relationship between free valproic acid and total valproic acid concentrations. Fifty seven paired measurements of valproic acid concentration from 22 patients were included in this figure. Each data point represents the mean value of measurements from a single patient. VPA = valproic acid; SD = standard deviation.
